IDEAYA Biosciences R&D Day
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good afternoon. I wanted to welcome everyone to sunny London. Thank you for taking time out of your very busy schedule. We have a lot we are going to cover today, and so thank you again for the time this afternoon. Our presenters today, Dr. Frank McCormick from UCSF. I will also be presenting the introduction portion. We will also have Dr. Michael White, our President of R&D, and Dr. Theo Ross, our Chief Development Officer. For today's presentation, we will cover several different aspects of the pipeline. 2026 has been a year of significant importance for IDEAYA. This was the year where we filed our first NDA for darovasertib. We also presented as an ASCO oral presentation the top-line results in the first-line metastatic uveal melanoma setting.
In addition, we did note recently that our plan to advance our second program, our DLL3 ADC program, into phase III studies, both in the small cell lung cancer setting, as well as neuroendocrine carcinoma. Today, our focus will be on our third driver in our clinical pipeline, and that is in the MTAP deletion CDKN2A setting. People may have seen earlier today, we did announce the announcement of our development candidate, IDE101, which Mike will profile in depth in terms of why we are excited about this molecule, why we believe it is a key enabler in a very key genetic setting called CDKN2A, which we believe will enable key combinations, both with PRMT5 as well as pan-RAS. In addition, today, we will provide a clinical program update on PRMT5, IDE892. Here, we will show the first time we are sharing both safety data, PK data, as well as human pharmacodynamic data.
Next, we will also cover IDE574. This is our phase I/II KAT6/7 inhibitor that we are now evaluating for monotherapy, including indications such as breast cancer. We will also show some early data as it relates to why we believe this combination is potentially compelling, specifically with pan-RAS inhibitors in the area of KRAS CRC. For those that have evaluated pan-RAS and potential resist mechanisms, we know that roughly half of the resistance mechanisms that have been associated with pan-RAS are not genetic mutation-driven. In particular, related to a specific bypass mechanism that is connected to the Wnt/MYC pathway. For those that may be familiar, RAS is specifically in the MAP kinase pathway. Mike will walk through in depth of why we believe these two pathways converge and where we believe this creates a therapeutic opportunity for KAT6/7 to be combined with pan-RAS, specifically in the indication of KRAS CRC.
As I mentioned earlier, CDKN2A, here, there is going to be several key pieces that we will highlight. One, for those that may be less familiar with CDKN2A is considered one of the most important tumor suppressor genes in cancer. As frequent and as important as other tumor suppressor genes, several you probably are aware of, including P53. The reason for this is the critical role of several key tumor suppressor proteins are impacted specifically by CDKN2A, which we will cover here in a little bit, including P14 and P16 as well. As we look forward and as we think about some of the key data that was presented in 2026 was really a remarkable year, not just for pan-RAS, but also for PRMT5. We saw with pan-RAS, obviously key data that was presented at ASCO, where we saw doubling survival in the refractory setting of pancreatic cancer.
We also saw in 2026 the first proof of concept data combining pan-RAS with PRMT5, generating what we believe is key first clinical proof of concept that we believe may create a potential registrational path forward in pancreatic cancer. Now the CDKN2A portion comes into play, which is the connection between MTAP and CDKN2A. CDKN2A and MTAP are both located on the 9p21 chromosome, and when MTAP is deleted, CDKN2A is almost always co-deleted. What is the significant importance of that? First, we know that, as I mentioned earlier, CDKN2A's role as a key tumor suppressor gene, but we've also generated data, which we're going to show to you today, which is one of the most significant combination synergy effects we've actually observed is with this mechanism of CDKN2A and pan-RAS.
We believe this is partly linked to, which Mike will go through in detail, two tumor suppressor proteins that we've seen impacted when you combine these two mechanisms together, and that's related to P21 and P27. This data has never been presented or shared before, period, in any forum that we're aware of, but we think this is critical data that really supports the mechanistic rationale of this combination. Why should we all care about this? The reason why we should care is because CDKN2A deficiency, which is defined by deletion, methylation, and mutation, is prevalent in roughly 70% of pancreatic cancer. Now you can imagine a situation where we combine this agent with pan-RAS, address the majority of that patient population, and as I noted earlier, MTAP and CDKN2A is almost always co-deleted.
Now we can use this as a plug-and-play combination across any MTAP-deleted solid tumor indication with these two now wholly owned assets. With that, we will then proceed to the next section. That provides sort of a high-level summary and hopefully a couple of key touchpoints that you're going to hear across this presentation today. When you take a step back on what is driving our strategy and combinations in the area of pancreatic cancer, CRC, and lung cancer, specifically with the genetic settings of MTAP, CDKN2A, and KRAS in mind, it's really driven by these two core areas. One is this concept of tumor heterogeneity, which as we know today, that cancers, in particular pancreatic cancer, KRAS, yes, we believe is a key driver oncogene in that indication.
However, these patients have other significant genetic mutations that we believe are driving those cancers, specifically MTAP deletion and CDKN2A. The targets that we'll focus on here as part of this discussion will be largely focused on PRMT5 and CDKN2A, and the key genetic mutations that we'll cover, as I noted earlier, will be focused on MTAP, CDKN2A, and the KRAS setting. The second area is around this concept of tumor plasticity or adaptive plasticity. Essentially what this really refers to is changes in the tumor that are causing resistance to pan-RAS specifically that are not driven specifically by genetic mutations. As I mentioned earlier, we believe there's a significant interplay between the MAP kinase pathway and RAS and the Wnt/Myc signaling pathway, which we believe creates this therapeutic opportunity with KAT6/7, and we'll go through that data as well.
So as you can see, in 2026, we believe we have now built one of the broadest pipelines in precision medicine oncology today across several key areas, including IDE892, our PRMT5. We will cover here why we believe we have a potential best-in-class molecule. As noted earlier, we will cover several key parameters, and really the three critical product profiles that we believe are important for first-in-class agent. First is around drug-drug interactions, in particular around CYP3A4. So we will share some data, including some early clinical data that we have in combination with a CYP3A4-mediated agent of IDE397, our MAT2A inhibitor. Second is around the importance of having a non-brain-penetrant molecule. We believe because of the mechanism and role of both PRMT5 and MAT2A, specifically in RNA splicing, is that you do not want that activity specifically in the brain because of the known role of RNA splicing in cognition specifically.
Then the third component is around MTA cooperative selective binding versus SAM cooperative binding, and ultimately we believe where this will translate is what type of therapeutic window can we generate it specifically as it relates to myelosuppression. So Dr. Ross here will cover the safety data to hopefully establish that we believe we are seeing a very clean safety profile as well. Next, for KAT6/7, we will also share, as I mentioned earlier, some early clinical data. We will share early safety data. We will also share some PD data as well as some case studies for several of these programs. So you will get to see some early clinical efficacy data across these programs. The last part that I will mention, which we will also have a short section on, is around how we are implementing AI in our drug discovery process.
And we have utilized this both for our CDKN2A program, KAT6/7, as well as what we are doing in the next generation oncogene area as well, which Mike will cover here shortly. So one of the key concepts that we want to cover in today's R&D presentation is what we believe could be potentially a new patient treatment paradigm as it relates to how we think about rational combinations in precision oncology. And this is the idea to not just hit the key driver oncogene, but through the combination also addressing the key tumor suppressor loss gene. As noted earlier, we have now clinical proof of concept about combining both a RAS inhibitor with a PRMT5 inhibitor in the MTAP/KRAS indication of PDAC, which we believe represents about 40% of that population.
Then we will now showcase a second example of how we are targeting both a key tumor suppressor loss, this time CDKN2A, in combination with a RAS inhibitor. And we think this continues to validate this hypothesis of potentially a new way to really pursue combinations to drive benefit to these patients. So a lot of this I have covered already, but this, I would say, hopefully highlights the depth and the breadth of the combination activities that we are pursuing. As you can see, we have extensive efforts across PDAC, planned activities across also non-small cell lung cancer and CRC. As people may be aware, we have two collaborations that are ongoing with Roche, one with our pan-RAS inhibitor, specifically to treat MTAP deletion PDAC patients, and then more recently, a combination with KRAS G12D to target KRAS G12D pancreatic cancer patients.
The first combination, we anticipate we will start dosing our first patient by the end of the year, and then our KRAS G12D should be dosing patients by our anticipated goal is early next year. Look for us to continue to push these combinations forward, both through wholly owned combinations that IDEAYA controls, as well as more collaborations that we anticipate forming through biopharma partnerships. With that, we will go ahead and introduce our next speaker, Dr. Frank McCormick. Dr. McCormick does not need much of an introduction, has been truly one of the key pioneers in RAS research for many decades. I have known Frank for a long time, and I have to say, I think this is the first time I have seen him wearing a tie. Thank you, Frank, for doing that.
We really appreciate your time and hearing your insights both in what the opportunities in RAS have been and also what are the future key challenges as we look forward into the future.
Thank you very much for the introduction. It is great to be here with all of this team. Good afternoon to all of you from rainy and cold San Francisco. I will speak to some- It is a beautiful switch, I am sure you all will agree. Switches back and forth from the off state into the on state, depending on whether it is bound to GTP or GDP. This protein does not present any obvious pockets to which a small molecule combined until very recently. The technology was just not there to find drugs that hit RAS proteins directly. Next slide, please, Mike. Back in 1992, when we started Onyx actually to target this pathway, the pathway looked like on the left. We have RAS proteins cycling between the off state and the on state.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
10 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
